Cargando…
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
BACKGROUND: Standard of care treatment for multicentric lymphoma in dogs remains doxorubicin (DOX)‐based combination chemotherapy, but owners may hesitate to commit the time and financial resources to complete such a protocol, typically requiring 12–16 visits. Rabacfosadine (RAB), a double prodrug o...
Autores principales: | Thamm, D.H., Vail, D.M., Post, G.S., Fan, T.M., Phillips, B.S., Axiak‐Bechtel, S., Elmslie, R.S., Klein, M.K., Ruslander, D.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435064/ https://www.ncbi.nlm.nih.gov/pubmed/28370378 http://dx.doi.org/10.1111/jvim.14700 |
Ejemplares similares
-
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
por: Cawley, Jacob R., et al.
Publicado: (2020) -
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
por: Weishaar, Kristen M., et al.
Publicado: (2021) -
Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
por: Burton, J.H., et al.
Publicado: (2015) -
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials
por: Saba, Corey F., et al.
Publicado: (2020) -
c‐Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine
por: Weishaar, K.M., et al.
Publicado: (2017)